The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Yap Chee Keong | Director | Grant(A) | 32K | — | — |
| Aug 13, 2026 | Tan Lee Su-Leng | Chief Executive Officer, Director, 10% Owner | Grant(A) | 339K | — | — |
| Aug 13, 2026 | Low Jook Yuen | Director | Grant(A) | 16K | — | — |
| Aug 13, 2026 | Chong Set Fui | Chief Financial Officer | Grant(A) | 97K | — | — |
| Aug 13, 2026 | Bin Abdul Hamid Muhammad Azrul | Director | Grant(A) | 32K | — | — |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: BioNexus Gene Lab Corp, SEC CIK 0001737523. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under BGLC and shows every filing by that issuer.
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-12. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for BGLC